University of Pittsburgh researchers have developed a novel therapeutic approach using Nsp-Interleukin-10 (Nsp_IL10) fusion proteins to treat chronic inflammatory diseases such as osteoarthritis (OA). The delivery of this engineered molecule at the early stages of OA aims to reduce inflammation and pain, and delay tissue degeneration, offering a potential breakthrough in managing this prevalent degenerative joint disease.
